Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression
The DOI matches its Crossref record; 57 of the 58 references it cites were found in a registry or an index.
Abstract
Background and objective Affective disorders account for most cases of suicide. The pharmacological arsenal to treat suicidality is limited and available agents take too long to take effect. A large body of evidence shows optimal results of ketamine for treating depression, but the evidence concerning suicidality has not been fully described. We report the first real-world study of severely depressed patients presenting with suicide ideation who were treated with repeated administration of subcutaneous esketamine.Methods We analyzed data from 70 acutely depressed subjects diagnosed with resistant major depressive disorder or bipolar depression. Subjects were administered subcutaneous esketamine once a week for 6 weeks. The primary efficacy endpoint, the change from baseline to 24-h post-administration 6 in the item 10 Montgomery-Åsberg Depression Rating Scale score, was analyzed using a mixed-effects repeated-measures model.Results There were significant effects for time on item 10 Montgomery-Åsberg Depression Rating Scale scores (p < 0.0001) but not for a time × diagnosis interaction (p = 0.164) from baseline to the end of the study. Efficacy of esketamine did not differ between groups (major depressive disorder vs bipolar depression) at any timepoint. Statistical significance on suicidality scores was observed from 24 h after the first administration (p < 0.001), and a further reduction was observed with repeated administrations. Esketamine was safe and well tolerated. Mean heart rate remained stable during the administrations and the blood pressure increase was self-limited.Conclusions Repeated subcutaneous esketamine administration had significant anti-suicidality effects in both major depressive disorder and bipolar groups, with a rapid onset of action and a good tolerability profile. Large randomized controlled trials are warranted to confirm these preliminary findings.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Previous research echoes these results, with multiple studies finding high rates of remission for suicidal ideation after a single ketamine infusion in patients hospitalized for acute suicidal ideation [77][78][79].”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [79]
Citations
Cites
1 retracted
Larkin, G. L., & Beautrais, A. L. (2011) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000629 · Cited by 258
RetractedDiagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
(1998) · PubMed · Cited by 10,216
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
The Three-Step Theory (3ST): A New Theory of Suicide Rooted in the “Ideation-to-Action” Framework
Klonsky, E. D., & May, A. M. (2015) · International Journal of Cognitive Therapy · doi:10.1521/ijct.2015.8.2.114 · Cited by 1,799 · cited 2×
“In addition, individuals who experience different manifestations of suicidality such as suicidal thoughts, plans, and behaviors often complete a suicide [6].”
BackgroundMeltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393
Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205
Psychiatric diagnoses in 3275 suicides: a meta-analysis
Arsenault-Lapierre, G., Kim, C., & Turecki, G. (2004) · BMC Psychiatry · doi:10.1186/1471-244x-4-37 · Cited by 985
Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis
Cipriani, A., Hawton, K., Stockton, S., & Geddes, J. R. (2013) · BMJ · doi:10.1136/bmj.f3646 · Cited by 920
Research works printed but not linked: 1
- Jacobs DG, Baldessarini RJ, Conwell Y, Fawcett JA, Horton L, Meltzer H, et al. Assessment and treatment of patients with suicidal behaviors. APA practice guidelines. Washington, DC: American Psychiatric Publishing; 2010.
Cited by
Ketamine in neuropsychiatric disorders: an update
Johnston, J. N., Kadriu, B., Kraus, C., Henter, I. D., & Zarate, C. A. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01632-1 · Cited by 108
Psychedelics in the treatment of eating disorders: Rationale and potential mechanisms
Calder, A. E., Mock, S., Friedli, N., Pasi, P., & Hasler, G. (2023) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2023.05.008 · Cited by 55
Ketamine and Esketamine for Depression in Daily Practice: Opportunities and Challenges
Singh, B. (2024) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001898 · Cited by 20
Early effects predict trajectories of response to esketamine in treatment-resistant depression
Estrade, I., Petit, A., Sylvestre, V., Danon, M., Leroy, S., Perrain, R., Vinckier, F., Mékaoui, L., Gaillard, R., Advenier-Iakovlev, E., et al. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.09.030 · Cited by 19
Wilkowska, A., & Cubała, W. J. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1322752 · Cited by 20
Metadata
- Authors
- Surjan, J., Grossi, J. D., Del Porto, J. A., Delfino, R. S., de Oliveira Cerqueira, R., Lucchese, A. C., Magalhães, E., Del Sant, L. C., Tuena, M. A., Nakahira, C., Fava, V. A. R., Steglich, M. S., Abdo, G. L., Barbosa, M. G., Sarin, L. M., & Lacerda, A. L. T.
- Affiliations
- Universidade Federal de São Paulo (BR)
- Corresponding author
- Lacerda, Acioly Luiz Tavares
- ORCID
- Venue
- Clinical Drug Investigation
- Published
- 2022-08-31
- Volume
- 42
- Issue
- 10
- Pages
- 865-873
- ISSN
- 0114-2402 (ISSN-L)
- 1173-2563
- 1179-1918
- OpenAlex
- W4293767515
- Cited by
- 19
- References
- 58
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 4 · 2023: 9 · 2022: 2
- FWCI
- 2.54
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Clinical Drug Investigation (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
- Keywords
- esketamine, suicidality, suicidal ideation, major depressive disorder, bipolar depression, treatment-resistant depression, drug safety and tolerability, ketamine
- MeSH terms
- Administration, Intranasal, Antidepressive Agents, Bipolar Disorder, Depressive Disorder, Major, Major Depressive Disorder, Double-Blind Method, Humans, Ketamine, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression. https://app.cochat.ai/papers/10.1007/s40261-022-01193-z
- The paper
- Surjan, J., Grossi, J. D., Del Porto, J. A., Delfino, R. S., de Oliveira Cerqueira, R., Lucchese, A. C., Magalhães, E., Del Sant, L. C., Tuena, M. A., Nakahira, C., Fava, V. A. R., Steglich, M. S., Abdo, G. L., Barbosa, M. G., Sarin, L. M., & Lacerda, A. L. T. (2022). Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression. Clinical Drug Investigation. https://doi.org/10.1007/s40261-022-01193-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.